Role of ROS1 fusion gene mutations in diagnosis and treatment of non-small cell lung cancer
10.3969/j.issn.1000-8179.2019.05.084
- VernacularTitle:ROS1融合基因突变在非小细胞肺癌诊断与治疗中的研究进展*
- Author:
Jiang WEI
1
Author Information
1. 浙江大学医学院附属第一医院肿瘤内科(杭州市310000
- Keywords:
ROS1 gene;
non-small cell lung cancer (NSCLC);
crizotinib;
drug resistance
- From:
Chinese Journal of Clinical Oncology
2019;46(5):257-262
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of ROS1 gene rearrangement/fusion in non-small cell lung cancer (NSCLC) is about 1%-2%. The advent of tar-geted drugs for ROS1 gene fusion has significantly improved the quality of life and total survival of NSCLC patients with ROS1 fusion;however, acquired drug resistance is still present in most patients after continuous treatment. This review has summarized the back-ground of the ROS1 fusion gene, detection method, clinical efficacy of ROS1-targeted therapy, and strategy and prospect of drug resis-tance.
